Bacterial and Viral Specimen Collection - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bacterial and viral specimen collection market size was valued at USD 23.52 billion in 2025 and is estimated to grow from USD 26.81 billion in 2026 to reach USD 51.70 billion by 2031, at a CAGR of 14.03% during the forecast period (2026-2031). This report is Segmented by Product Type (Bacterial, Viral Specimen Collection), Specimen Type (Respiratory, Blood, Uand More), Application (Diagnostics, Research, Others), End User (Hospitals and Clinics, and More), Technology (Manual, Automated, Digital Sample Tracking), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Bacterial and Viral Specimen Collection Market Trends and Insights

Rising Infectious Disease Testing Volume Sustains Structural Demand

The market for bacterial and viral specimen collection is thriving, driven by an uptick in testing for infectious diseases. This surge spans respiratory pathogens, bloodstream infections, and extensive surveillance initiatives. Routine care sees elevated specimen volumes due to endemic respiratory infections. Meanwhile, heightened demand for standardized bacterial collection arises from bacteremia surveillance and antimicrobial resistance programs. As national surveillance frameworks become more structured, there's a noticeable shift in procurement: a move towards certified kits, distancing from generic low-cost products. This shift is significant; once protocols for collection are standardized, replacements tend to adhere to these approved formats rather than being subject to discretionary purchases.

Expanding Molecular Diagnostics And PCR Adoption Elevates Collection Standards

The market for bacterial and viral specimen collection is on the rise, propelled by the adoption of RT-PCR, multiplex PCR, and next-generation sequencing in clinical labs. These advanced platforms necessitate stringent control over pre-analytical variables. As a result, factors like swab material, transport media composition, and storage conditions have gained prominence compared to older testing methodologies. This evolution amplifies the value of molecularly compatible collection products, diminishing the relevance of basic commodity formats in sophisticated labs. Furthermore, it bolsters suppliers capable of validating the entire workflow, from collection to assay performance. BD expanded its BD MAX System menu in December 2025 with IVDR-certified VIASURE assays through its collaboration with Certest Biotec.

Price Sensitivity In Commodity Swabs And Transport Media Compresses Margins

The bacterial and viral specimen collection market faces significant pricing pressure in its commodity segment. Standard swabs and traditional transport media are often procured through large tenders, favoring suppliers with scale or low-cost manufacturing. Group purchasing organizations in North America and Europe play a key role in driving down prices for routine products. This environment challenges mid-sized manufacturers to maintain margins unless they offer differentiated materials or workflows. In 2025, Puritan Medical Products emphasized domestic manufacturing as a stable supply option amidst tariff-related dynamics, though premium pricing continues to compete with procurement systems focused on minimizing unit costs. The market remains divided between premium validated products and a commodity tier constrained by price competition.

Other drivers and restraints analyzed in the detailed report include:

• Decentralized Testing, Home Collection, And DTC Sampling Reshape Collection Economics
• Ambient-Stable Transport Media Adoption Expands Market Access In Resource-Limited Settings
• Regulatory Burden For Validation, Shelf-Life, And Compatibility Testing Creates Entry Barriers

Segment Analysis

In 2025, viral specimen collection accounted for 57.45% of revenue, maintaining its central role in the market due to high routine testing volumes for respiratory viruses. Influenza, RSV, and SARS-CoV-2 testing continue to dominate across hospitals, clinics, and public health systems. Viral transport media and flocked swabs drive revenue in this segment, offering broad assay compatibility and stable specimen integrity. COPAN's UTM Universal Transport Medium remains a key product supporting respiratory testing workflows.

Bacterial specimen collection is projected to grow at a 15.99% CAGR through 2031, driven by expanding antimicrobial resistance surveillance. Demand for bacterial products is fueled by bloodstream infection testing, wound culture collection, and stewardship-linked sampling programs. COPAN's launch of LBM CABroth in May 2026 for Candida auris surveillance highlights the diversification of bacterial collection portfolios. Urine containers, culture media, and tissue collection kits also play a critical role, as bacterial testing is integral to clinical decision-making.

Respiratory specimens held 42.35% of the market share in 2025, reflecting their dominance in seasonal infection testing and outbreak responses. National surveillance systems and clinical workflows rely heavily on nasopharyngeal and throat collections for diagnostics like influenza, COVID-19, and Group A Streptococcus. Continuous consumption of respiratory collection kits ensures stable demand.

Saliva specimens are expected to grow at a 17.95% CAGR through 2031, driven by non-invasive testing preferences, ease of self-collection, and the rise of direct-to-consumer and remote research programs. Salimetrics' launch of Participant Sampling Packs in October 2025 supports remote collection and sample integrity. Blood specimens remain vital for research, while stool, wound, and tissue samples cater to specialized testing niches.

Complete Report Scope:

• By Product Type
  • Bacterial Specimen Collection
    • Swabs
    • Transport Media
    • Blood Collection Kits
    • Culture Plates and Media
    • Biopsy and Tissue Collection Kits
    • Urine Collection Containers
    • Other Specialized Bacterial Collection Devices
  • Viral Specimen Collection
    • Viral Transport Media
    • Swabs
    • Blood Collection Tubes
    • Saliva Collection Kits
    • Sputum Collection Containers
    • Stool Collection Kits
    • Other Specialized Viral Collection Devices
• By Specimen Type
  • Respiratory Specimens
  • Blood Specimens
  • Urine Specimens
  • Wound and Tissue Specimens
  • Saliva Specimens
  • Stool Specimens
  • Other Specimen Types
• By Application
  • Diagnostics
  • Research
  • Others
• By End User
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Clinical Research Organizations
  • Others
• By Technology
  • Manual Collection Systems
  • Automated Collection Systems
  • Digital Sample Tracking And Traceability
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America accounted for 42.55% of the revenue in the bacterial and viral specimen collection market, driven by its extensive reference laboratory network and consistent investments in preparedness. The region's strong molecular diagnostics base boosts demand for validated collection methods and integrated workflows. The United States leads as a major testing market and an early adopter of home and decentralized collection models. BD's FDA submission for its at-home Onclarity HPV self-collection method and Puritan's PurSafe Plus launch in 2025 highlight North America's influence on room-temperature and non-clinical specimen logistics. Canada supports this growth through province-led public laboratory systems moving toward standardized and automated pre-analytical handling.

Europe remains a key region in the bacterial and viral specimen collection market, with certification requirements shaping portfolio diversity and supplier strategies. Full IVDR enforcement has increased recertification challenges for swabs, transport media, and specimen kits, favoring manufacturers with strong compliance capabilities. Germany and the UK are significant markets due to their public health surveillance and hospital microbiology networks requiring standardized collection protocols. BD's expansion of its BD MAX system with IVDR-certified VIASURE assays in 2025 reflects Europe's push for alignment between assay systems and collection tools.

Asia-Pacific is projected to grow at a 16.26% CAGR through 2031, making it the fastest-growing region in the bacterial and viral specimen collection market. Growth is driven by China's hospital laboratory expansion, India's infectious disease surveillance, and South Korea's molecular diagnostics manufacturing base. Japan and Australia contribute with high testing intensity and early adoption of automation-compatible formats. South America is advancing through Brazil and Argentina, where public laboratory networks and private diagnostic chains are adopting standardized kit procurement.

List of Companies Covered in this Report:

• Beckton Dickinson
• bioMérieux
• Cardinal Health
• COPAN Diagnostics Inc.
• DiaSorin
• Roche
• Greiner Bio One International
• Hardy Diagnostics
• HiMedia Laboratories Pvt. Ltd.
• Longhorn Vaccines and Diagnostics, LLC
• Medical Wire and Equipment Co. Ltd.
• Medline Industries
• Pretium Packaging, L.L.C.
• Puritan Medical Products Company I, LP
• QuidelOrtho
• Spectrum Solutions, LLC
• Thermo Fisher Scientific
• Titan Biotech Ltd.
• Trinity Biotech plc

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support